RESEARCH ARTICLE

CHANGES IN LIPID PROFILES AND OTHER BIOCHEMICAL PARAMETERS IN HIV-1 INFECTED PATIENTS

**Brahmareddy Malapati, Bhavita Patel, Rita M Shah, Nillawar AN,
Madhu Latha, Durgabhavanireddy Vajrala, Nadeem Shaikh**

Department of Biochemistry, SBKS Medical Institute & Research Centre, Pipariya, Waghodia, Gujarat, India

Correspondence to: Brahmareddy Malapati (brahmareddy.malapati@gmail.com)

ABSTRACT

Background: Abnormalities of lipid metabolism are common in human immunodeficiency virus (HIV) infected patients and tend to be accentuated in those receiving antiretroviral therapy, particularly with protease inhibitors (PIs). However, there is a dearth of information on serum lipid profiles and biochemical parameters among treatment-naive HIV-positive patients in our environment.

Aims & Objective: To study changes in lipid profiles and other biochemical parameters in HIV-1 infected patients.

Materials and Methods: A prospective, observational study was carried out on HIV- 1 infected patients attending anti-retroviral drug (ARV) clinic and who were started HAART between December 2012 and December 2013 from Gujarat state. Clinical, anthropometrical and laboratory data were recorded at the start of the study and after one years of HAART. Patients' data were collected in a computerized database for later statistical analysis; Categorical variables were analyzed with the χ^2 test, or the Fisher exact test when necessary.

Results: We found that after 12 months of highly active antiretroviral therapy (HAART), there was a significant increase in serum lipids. After 12 months of HAART, renal impairment was associated with a low increase in mean HDL and a high increase in triglycerides (TG). In conclusion, abnormality of serum lipid is common and showed female preponderance among treatment-naive HIV patients in our environment.

Conclusion: Patients with HIV infection on HAART should be screened for lipid disorders given their high prevalence as observed in this study, because of its potential for morbidity and mortality in patients on HAART.

Key Words: Lipid Profile; HIV Infection; Highly Active Antiretroviral Therapy (HAART)

Introduction

The availability of potent combination antiretroviral regimens has resulted in a dramatic reduction in human immunodeficiency virus (HIV-1) associated morbidity and mortality in the developed world.[1]

However, the optimism generated by such treatment has been tempered by the recognition of an increasing array of adverse metabolic effects, including insulin resistance and glucose intolerance, dyslipidaemia, changes in body fat distribution, lactic acidemia, and osteopenia.[2-7] Multiple abnormalities in lipid metabolism were reported in HIV-1 infected patients. Changes in blood lipids occur naturally during the course of HIV infection, with decreases in early phase of the infection in both total cholesterol (TC) and high-density lipoprotein (HDL) cholesterol, and increases later in triglycerides (TGs).[8] Infection with HIV-1 is known to increase plasma TG levels by decreasing the number of circulating lipoproteins, a process considered to be the result of reduced lipoprotein lipase or by stimulating hepatic lipid synthesis through an increase in hepatic fatty acid synthesis or an increase in re-esterification of fatty acid derived from lipolysis.[9] However, highly active antiretroviral therapy (HAART) also leads to lipid changes with increases in both TGs[10] and TC[11]. While increases in TC during therapy may represent a return to pre-infection levels to some degree.[11] HAART is associated with an increased risk of CVD such as myocardial infarction.[12] Few studies has studied lipid profiles of patients on HAART but they were either of short duration or based on a small number of patients (less than 100).[7-9,11,12] Therefore, present study was designed for evaluating lipid profiles for antiretroviral-naïve patients on nucleotide reverse transcriptase inhibitor (NNRTI)-based HAART for medium term.

Materials and Methods

Patients and Methods

A prospective, observational study was carried out on HIV- 1 infected patients attending anti-retroviral drug (ARV) clinic and who were started HAART between December 2012 and December 2013 from Gujarat state.

Classification system for HIV infection and expanded AIDS surveillance case definition for adolescents and adults was used for inclusion of patient in the study.[13]

Patients of 18 years age and either gender were enrolled in this study. All the patients were prescribed Stavudine (d4T) (one tablet of 40 mg twice daily) and Lamivudine (3TC) (one tablet of 150 mg twice daily). In addition, patients were randomly allocated to nevirapine (NVP) (200 mg daily for 2 weeks and then twice daily thereafter), or efavirenz (EFV) (one tablet of 600 mg once daily at bed time or one tablet of 800 mg once at bed time) depending on whether they had associated opportunistic infection treatment, especially anti-tuberculosis (TB) drugs.

Clinical, anthropometrical and laboratory data were recorded at the start of the study and after one years of HAART. Fasting blood glucose, serum TC, TGs, HDLs, low-density lipoproteins (LDLs), urea, and creatinine serum enzyme alanine aminotransferase (ALT) were estimated by an automated clinical chemistry autoanalyzer (Hitachi 902 Roche Diagnostic GmbH, Mannheim Germany). The CD4 + T lymphocyte cell count was estimated by CyFlow Counter (Partec GmbH, Gorlitz Germany). Blood was drawn after a 12-hour fast for the measurement of plasma lipids. Diagnosis of dyslipidemia was based on cholesterol levels 5.18 mmol/L and TG levels 1.69 mmol/L.

Outcome Measures

The mean percentage changes of total TG, TC, HDL and LDL between baseline (month 0) and month X after start of treatment were determined for each individual patient using the formula by Van Leth and colleagues.[14]

$$\text{Increase (\%)} = \frac{C_X - C_0}{C_0} \times 100$$

Where, C_X = Concentration at month X (X is the study end point at which follow up takes place - 12 months) after the start of treatment; C_0 = Concentration at month 0 (baseline or month 0). A body mass index (BMI) above 25 kg/m^2 was considered to be high.

Statistical Analysis

Patients' data were collected in a computerized database for later statistical analysis; Categorical variables were analyzed with the χ^2 test, or the Fisher exact test when necessary. Comparison of quantitative variables prior to starting HAART and at one year was performed with the paired student t-test or the Mann-Whitney U-test for variables that did not follow normal distribution. Quantitative variables were compared using Student's t-test or the Mann-Whitney U-test for variables that did not follow normal distribution. The alpha level was set at 0.05.

Results

Clinical Parameters of the Patients: Out of total 229 patients included in this study, 17 did not complete the programmed follow-up. There were four AIDS-related deaths; the rest defaulted follow-up for reasons unknown to us. The mean age of the study population was 46.3 ± 9.3, males being older than females in general (P = 0.03). The majority of patients had a heterosexual source of exposure to the virus; almost half of the participants had AIDS either by clinical or immunological parameters and one out of every five patients was overweight (BMI, 25 kg/m^2)

Baseline association between lipid profiles, some metabolic and HIV-associated variables: The female gender was associated with statistically significant elevation of all serum lipids at baseline, while no difference was observed between lipid profiles of hypertensive and normotensive cohorts. Diabetes mellitus was associated with a significant elevation in mean LDL. Overweight/obese patients had high TG and low HDL cholesterol. Hepatitis B surface antigen and/or hepatitis C antibody positivity had similar lipid profiles to hepatitis B- or C-negative patients, while the presence of TB was associated with high TG. The presence of AIDS-defining illnesses or immunological AIDS (CD4 count, 200 cells/μL) was associated with a statistically significant elevation in mean LDL and TC, as depicted in Table 1.

Changes in the level of serum lipids, CD4 count and some biochemical parameters after 12 months of HAART: Table 2 shows the changes in lipid profiles after 12 months of HAART. As shown, there were significant increase in TC, TG, HDL and LDL. Fasting blood glucose also increased, as did urea. There was a significant decline in creatinine, but ALT remained unchanged throughout the study period. The CD4 count increased significantly from 246.2 ± 166.5 to 437.2 ± 274.6, and there was an observed significant weight gain as evidence by increase in BMI from 23.3 ± 4.2 to 25.6 ± 3.9. Younger participants (46 years) had a significant mean change in their lipid parameters in comparison to older participants (47 years) after 12 months of HAART as depicted.

Changes in lipid profiles in some metabolic and HIV-associated variables after 12 months of HAART: Taking gender and some metabolic and HIV-associated variables into account, renal impairment was associated

with significantly low increase in mean HDL and high increase in TG. Patients with metabolic and HIV-associated variables had similar changes in lipid parameters to other cohorts.

Percentage change in mean lipid parameters after 12 months of HAART: After 12 months of HAART, the percentage mean change of the lipid parameters is shown in Figure 2. The mean TG changed by 23.3% over the study period, while LDL, HDL and TC changed by 20.9%, 8.5% and 13.7% respectively.

Table-1: Baseline association between lipid profiles and HIV-associated variables.

Characters		LDL	HDL	TG	TC
Sex	Female	2.79 ± 1.35	1.53 ± 0.76	1.46 ± 0.20	4.78 ± 1.31
	Male	2.42 ± 1.16	1.31 ± 0.76	1.12 ± 0.22	4.28 ± 1.42
	P-value	0.027	0.026	0.000	0.006
Hypertension	Yes	2.66 ± 1.20	1.46 ± 0.74	1.35 ± 0.19	4.62 ± 1.31
	No	2.62 ± 1.30	1.46 ± 0.76	1.34 ± 0.22	4.58 ± 1.43
	P-value	0.824	1.000	0.737	0.839
Diabetes Mellitus	Yes	2.67 ± 1.28	1.31 ± 0.75	1.21 ± 0.21	4.62 ± 1.44
	No	2.0 ± 0.93	1.44 ± 0.77	1.32 ± 0.21	4.58 ± 1.39
	P-value	0.014	0.554	0.068	0.920
BMI (kg/m2)	Underweight /normal	2.64 ± 1.27	1.59 ± 0.73	1.39 ± 0.18	4.36 ± 1.23
	Overweight /obese	2.83 ± 1.51	1.33 ± 0.73	1.27 ± 0.21	4.76 ± 1.44
	P-value	0.465	0.041	0.001	0.110
Tuberculosis	Yes	2.27 ± 1.08	1.41 ± 0.85	0.90 ± 0.21	3.95 ± 1.21
	No	2.65 ± 1.27	1.46 ± 0.76	1.35 ± 0.22	4.62 ± 1.40
	P-value	0.246	0.823	0.000	0.064
Hepatitis	Yes	2.42 ± 1.70	1.53 ± 0.91	1.37 ± 0.28	4.47 ± 1.54
	No	2.66 ± 1.27	1.44 ± 0.74	1.32 ± 0.21	4.58 ± 1.37
	P-value	0.445	0.945	0.336	0.740
AIDS	No	2.37 ± 1.24	1.39 ± 0.77	1.18 ± 0.20	4.25 ± 1.29
	Yes	2.82 ± 1.24	1.44 ± 0.77	1.37 ± 0.21	4.76 ± 1.39
	P-value	0.006	0.618	0.987	0.004

TC: total cholesterol; HDL: high density lipoprotein; LDL: low density lipoprotein; ALT: alanine aminotransferase; BMI: body mass index

Table-2: Changes in the level of serum lipids, CD4 count and some biochemical parameters after 12 months of HAART

Characteristics	Baseline	After 12 Months	*P*-value
Total Cholesterol (mmol/L)	4.54 ± 1.37	5.16 ± 1.58	0.0000
Triglycerides (TG)	1.29 ± 0.21	1.59 ± 0.22	0.000
HDL (mmol/L)	1.42 ± 0.78	1.54 ± 0.71	0.0440
LDL	2.63 ± 1.26	3.18 ± 1.23	0.000
ALT	33.89 ± 35.96	32.03 ± 27.30	0.466
Glucose	4.88 ± 1.76	5.34 ± 1.56	0.000
Creatinine	88.13 ± 32.63	83.08 ± 35.76	0.020
Urea	4.19 ± 1.88	4.83 ± 2.98	0.001
CD4 count	246.22 ± 166.54	437.23 ± 274.59	0.000
BMI (kg/m2)	23.27 ± 4.21	25.61 ± 3.89	0.001

TC: total cholesterol; HDL: high density lipoprotein; LDL: low density lipoprotein; ALT: alanine aminotransferase; BMI: body mass index

Discussion

Previous reports have demonstrated that HIV-infected patients exhibit multiple abnormalities in lipid metabolism both in pre-HAART[9,15-18] and post-HAART eras, especially with the use of protease inhibitors (PIs)[19-21]. Although the mechanisms that induce lipid abnormalities associated with potent antiretroviral therapy remain elusive, 22–24 several pathophysiologic models have been proposed to explain the development of dyslipidaemia in HIV-infected patients, involving several proposed interactions between the virus, antiretroviral therapies, and host factors.[18,25,26]

Metabolic derangement associated with the use of HAART calls for clinical concern about its use. Hyperlipidaemia, defined as an increase in TG and TC levels, was observed in this study, consistent with a previous report.[27] The baseline hypercholesterolemia was similar to findings by Bernasconi et al.[27] of 19% on a non-PI based regimen. However after 12 months on non-PI based HAART, the prevalence of hypercholesterolemia increased to 37.8%, which is comparable to 54% on a PI based regimen.[27] The results of this study contrast reports suggesting that dyslipidaemia is mainly due to the use of a PI based HAART regimen. Patients who demonstrate elevated TC and/or TG levels should be treated appropriately, in order to prevent the development and progression of atherosclerotic heart disease, stroke, and pancreatitis. The mean HDL determined before commencement of HAART in this study was 1.42 ± 0.77 mmol/L which is higher than other reports.[28-30]

Decreased levels of HDL occur at an early stage of HIV infection. Low HDL is a well-recognized independent risk factor for adverse cardiovascular outcomes and this has even been shown to be true in HIV-infected individuals, irrespective of other risk factors.[31] Several studies have shown that an HDL increase is associated with a significant decrease in mortality from coronary heart disease (CHD), independent of changes in LDL.[32] Other studies have associated the risk of cardiovascular disease (CVD) with low concentrations of HDL.[33,34] HDL dyslipidaemia (serum mean HDL, 1.03 mmol/L) as defined by the National Cholesterol Education Program (NCEP-ATP III) declined by 11.5% after12 months on HAART in this report. NNRTI regimens have been noted to have additional protective factors against low HDL.[35] This is especially strong with NVP.[36] This anti-atherogenic effect of a NVP-based regimen may be related to its protection against oxidative stress. 37 In a resource-limited setting, where access to PIs may be limited due to cost, this study has shown that a NVP-based regimen may offer the additional benefit of stabilizing lipid profiles, particularly in terms of enhancing HDL cholesterol.

Changes in blood lipids occur naturally during the course of HIV infection, with decreases early in the infection in both TC and HDL cholesterol and increases later in TGs.[38] However, HAART used in our cohort also leads to lipid changes, with increases in both TC[11] and TGs[10] as previously documented. While increases in TC during therapy may represent a return to pre-infection levels to some degree[11], the increased incidence of hypercholesterolemia after 12 months in our study may suggest that HAART is associated with an increased risk of myocardial infarction.[12]

The strengths of our study include the longitudinal design and 12 month follow-up, combined with our exclusion of pre-treated patients, and data once patients switched from one type of therapy to another. The main limitation of our study is the potential for confounds, which are inherent in every observational study.

The absence of any association between any of the lipid parameters and hypertension may be related to the duration of the hypertension, the degree of blood pressure control or the degree of immune suppression. Even in previously diagnosed hypertensive, who have been on medication or who have a positive family history of cardiovascular events in a first degree relative, there were no significant correlations between hypertension and abnormal lipid profiles, especially low HDL.[31] This suggests that HIV infection constitutes an additional and independent cardiovascular risk in hypertensive patients.

Studies have reported elevated TG was shown to positively correlate with interferon alpha, in patients with advanced disease/opportunistic infection. Markedly reduced immunity had to delayed clearance of plasma lipids due to reduced lipoprotein lipase activity.[39,40] We found no significant association between hepatitis serological status and abnormalities of the lipid profiles. Other studies have reported low LDL, low TC and low HDL in HIV-positive patients. In particular, those co-infected with hepatitis C and with advanced stages of liver disease tended to have low TC.[41-43] Though the findings were not significant, absolute values of these parameters were lower in those with hepatitis infection 36. TB is a common opportunistic infection in HIV/AIDS patients. With an HIV/TB co-infection, there is a synergism between the two infections that leads to progression of the two diseases and high mortality if not treated. As revealed in this study, HIV patients co-infected with TB had a significantly higher mean TG levels, and high but insignificant TC levels, compared with HIV-positive patients who were not co-infected. This may indicate an exaggerated state caused by HIV/TB co-infection.

Conclusion

Patients with HIV infection on HAART should be screened for lipid disorders given their high prevalence as observed in this study, because of its potential for morbidity and mortality in patients on HAART.

References

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338(13):853–60.
2. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12(7):F51–8.
3. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. "Buffalo hump" in men with HIV-1 infection. Lancet 1998;351(1906):867–70.
4. Saint-Marc T, Partisani M, Poizot-Martin I, Rouviere O, Bruno F, Avellaneda R, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 2000;14(1):37–49.
5. Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000;14:1309–16.
6. Roth VR, Kravcik S, Angel JB. Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis 1998;27(1):65–7.
7. Miller KK, Daly PA, Sentochnik D, Doweiko J, Samore M, Basgoz NO, et al. Pseudo-Cushing's syndrome in human immunodeficiency virus-infected patients. Clin Infect Dis 1998;27(1):68–72.
8. Sellmeyer DE, Grunfeld C. Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syn¬drome. Endocr Rev 1996;17(5):518–32.
9. Grunfeld C, Pang M, Doerrier W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance and cytokines in human immu¬nodeficiency virus infection and acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992;74(5):1045–54.
10. Thiebaut R, Dabis F, Malvy D, Jacqmin-Gadda H, Mercie P, Valentin VD. Serum triglycerides, HIV infection, and highly active antiretroviral therapy, Aquitaine Cohort, France, 1996 to 1998. Groupe d'Epidemiologie Cli¬nique du Sida en Aquitaine (GECSA). J Acquir Immune Defic Syndr 2000;23(3):261-5.
11. Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003;289(22):2978–82.
12. Friis-Møller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349(21):1993–2003.
13. Centers for Disease Control and prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA 1993;269(6):729–30.
14. Van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, Raffi F, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. Plos Med 2004;1(1):e19.

15. Constans J, Pellegrin JL, Peuchant E, Dumon MF, Pellegrin I, Sergeant C, et al. Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest 1994;24(6):416–20.

16. Fernández-Miranda C, Pulido F, Carrillo JL, Larumbe S, Gómez Izquierdo T, Ortuño B, et al. Lipoprotein alterations in patients with HIV infection: relation with cellular and humoral immune markers. Clin Chim Acta 1998;274(1):63–70.

17. Shor-Posner G, Basit A, Lu Y, Cabrejos C, Chang J, Fletcher M, et al. Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am J Med 1993;94(5):515–9.

18. Zangerle R, Sarcletti M, Gallati H, Reibnegger G, Wachter H, Fuchs D. Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation. J Acquir Immune Defic Syndr 1994;7(11):1149–56.

19. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidemia, and diabetes mellitus: a cohort study. Lancet 1999;353(9170):2093–9.

20. Dong KL, Bausserman LL, Flynn MM, Dickinson BP, Flanigan TP, Mileno MD, et al. Changes in body habi¬tus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART). J Acquir Immune Defic Syndr 1999;21(2):107–13.

21. Berthold HK, Parhofer KG, Ritter MM, Addo M, Wasmuth JC, Schliefer K, et al. Influence of protease inhibitor therapy on lipoprotein metabolism. J Intern Med 1999;246(6):567–75.

22. Matthews GV, Moyle GJ, Mandalia S, Bower M, Nelson M, Gazzard BG. Absence of association between individual thymidine analogues or nonnucleoside analogues and lipid abnor¬malities in HIV-1–infected persons on initial therapy. J Acquir Immune Defic Syndr 2000;24(4):310–5.

23. van der Valk M, Kastelein JJ, Murphy RL, van Leth F, Katlama C, Horban A, et al. Nevirapine containing anti¬retroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001;15(18):2407–14.

24. Carr A, Hudson J, Chuah J, et al. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multi¬centre study. AIDS 2001;15(14):1811–22.

25. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1–protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia and insulin resistance. Lancet 1998;351(9119):1881–3.

26. Mooser V, Carr A. Antiretroviral therapy-associated hyperlipidaemia in HIV disease. Curr Opin Lipidol. 2001;12(3):313–9.

27. Bernasconi E, Carota A, Magenta L. Metabolic changes in HIV-infected patients treated with protease inhibitors. 12th World AIDS Conference. 1998; Geneva, Switzerland.

28. Jacobson DL, Tang AM, Spiegelman D, Thomas AM, Skinner S, Gorbach SL, et al. Incidence of metabolic syn¬drome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr 2006;43(4):458–66.

29. Bernal E, Masia M, Padilla S, Gutierrez ZF. High density lipoprotein cho¬lesterol in HIV-infected patients: evidence for an association with HIV-1 viral load, antiretroviral therapy status and regimen composition. AIDS Patient Care STDS 2008;22(7):569–75.

30. Akpa MR, Agomouh D, Alasia DD. Lipid profile of healthy adult Nigerians in Port Harcourt, Nigeria. Niger J Med 2006;15(2):137–40.

31. Basa CB, Perez de Otajaza C, Carrio Montel D, Carrio Montel JC, Salguero Aparicio M, Del Romero Guerororo J. Lipid profile in untreated HIV positive patients. HIV infection: Cardiovascular risk factor? An Med Interna 2007;24(4):160–7.

32. Manninen V, Elo MO, Frick MH, Haapa K, Heinonen OP, Heinsalmi P, et al. Lipid alteration and decline in the incidence of coronary heart disease in the Helsinki heart study. JAMA 1988;260(5):641–51.

33. The lipid research clinics coronary primary prevention trial results. I. Reduction in the incidence of coronary heart disease. JAMA 1984;251(3):351–64.

34. Robins SJ. Targeting low high-density lipoprotein cholesterol for therapy: lessons from the Veterans Affairs High-density Lipoprotein Intervention Trial. Am J Cardiol 2001;88(12A):N19–3.

35. van der Valk M, Kastelein JJ, Murphy RL, van Leth F, Katlama C, Horban A, et al. Nevirapine-containing anti¬retroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001;15(18):2407–14.

36. Ige OM, Sogaolu OM, Ogunlade OA. Pattern of presentation of tuberculosis and the hospital prevalence of tuberculosis and HIV co-infection in University College Hospital, Ibadan: a review of five years. Afr J Med Sci 2005;34(4):329–33.

37. Masiá M, Padilla S, Bernal E, Almenar MV, Molina J, Hernández I, et al. Influence of anti-retroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients. Clin Ther 2007;29(7):1448–55.

38. Sellmeyer DE, Grunfeld C. Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syn¬drome. Endocr Rev 1996;17(5):518–32.

39. Constans J, Pellegrin JL, Peuchant E, Dumon MF, Pellegrin I, Sergeant C,, et al. Plasma lipid in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest 1994;24(6):416–20.

40. Gouni I, Oka K, Etienne J, Chan L. Endotoxin-induced hypertriglyceridemia is mediated by suppression of lipoprotein lipase at a post-transcriptional level. J Lipid Res 1993;34(1):139–46.

41. Jacobson DL, Tang AM, Spiegelman D, Thomas AM, Skinner S, Gorbach SL, et al. Incidence of metabolic syn¬drome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr 2006;43(4):458–66.

42. Aricio T, Celso S, Laura MD. Lipid and acute-phase protein alterations in HIV-1 infected patients in the early stages of infection: correlation with CD4 lymphocytes. Braz J Infect Dis 2001;5(4):192–9.

43. Polgreen PM, Fultz SL, Justice AC, Wagner JH, Diekema DJ, Rabeneck L, et al. Association of hypocholesterolaemia with hepatitis C virus infection in HIV-infected people. HIV Med 2004;5(3):144–50.